Skip to content
Advertisement

In this Aug. 17, 2018, file photo, Christine Gagnon, of Southington, Conn., holds a sign during a protest with others who have lost loved ones to OxyContin and opioid overdoses, outside the Purdue Pharma headquarters in Stamford, Conn. Gagnon lost her son Michael 13 months earlier. Nearly ten years ago, the blockbuster painkiller OxyContin was reformulated to discourage abuse by snorting and injecting, but it's unclear whether the harder-to-abuse format has decreased cases of addiction, overdose and death. (AP Photo/Jessica Hill, File)

In this Aug. 17, 2018, file photo, Christine Gagnon, of Southington, Conn., holds a sign during a protest with others who have lost loved ones to OxyContin and opioid overdoses, outside the Purdue Pharma headquarters in Stamford, Conn. Gagnon lost her son Michael 13 months earlier. Nearly ten years ago, the blockbuster painkiller OxyContin was reformulated to discourage abuse by snorting and injecting, but it's unclear whether the harder-to-abuse format has decreased cases of addiction, overdose and death. (AP Photo/Jessica Hill, File)

Featured Photo Galleries